Savara Inc - SVRA STOCK NEWS

Savara Inc. announced that molgramostim has received the Innovation Passport designation from the UK’s MHRA for treating autoimmune pulmonary alveolar proteinosis (aPAP). This designation is a step towards accelerating market access for innovative medicines in the UK. The drug is currently being investigated in the pivotal Phase 3 trial, IMPALA-2, and previously received Fast Track and Breakthrough Therapy designations from the FDA. The designation highlights the urgent need for effective treatments for aPAP, a debilitating condition.

Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced its management team will present at the Jefferies Healthcare Conference on June 8, 2022, at 1:00 pm ET in New York City. A live webcast will be available on the company's website and archived for 90 days. Savara's lead program, molgramostim, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and utilizes the investigational eFlow® Nebulizer System.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company specializing in rare respiratory diseases, will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 4:00 pm ET. The presentation will be broadcast live and available for 90 days on Savara's website.

Savara's leading program, molgramostim nebulizer solution, is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP) and is delivered via the investigational eFlow® Nebulizer System.

Savara Inc. (Nasdaq: SVRA) reports Q1 2022 net loss of $8.3 million ($(0.05) per share), improved from $10.2 million ($(0.13) per share) in Q1 2021. R&D expenses decreased 25.1% to $5.7 million due to the winding down of a previous program. The cash position stands at $152 million, sufficient to fund operations through 2025, as top line data from the Phase 3 IMPALA-2 trial of molgramostim is expected by the end of Q2 2024. The company emphasizes its strategic direction amidst global uncertainties.

Savara Inc. (NASDAQ: SVRA) announced on April 22, 2022, the grant of inducement awards to two new employees, comprising options to purchase 55,000 shares of common stock. The options have an exercise price of $1.23 per share, the closing price on the grant date. Each option features a 10-year term and vests quarterly based on the employee's continued service. Savara focuses on rare respiratory diseases, with its lead program, molgramostim nebulizer solution, in Phase 3 development for autoimmune pulmonary alveolar proteinosis.

Savara Inc. (NASDAQ: SVRA) has secured a $26.5 million term loan from Silicon Valley Bank to refinance its existing credit facility. The new loan features a lower interest rate of prime minus 0.50% and an initial 48-month interest-only period, enhancing the company's financial flexibility. With a cash position of approximately $161 million as of 2021, Savara believes it is funded through 2025, coinciding with the anticipated data read-out from its Phase 3 clinical trial of molgramostim.

Savara Inc. (Nasdaq: SVRA) provided a business update and reported its financial results for Q4 and FY 2021. The company is advancing its Phase 3 IMPALA-2 trial for molgramostim, activating most of the ~50 clinical sites, and anticipates top-line data by the end of Q2 2024. Financially, Savara ended 2021 with approximately $161M in cash and reduced its net loss to $11.3M in Q4 2021, compared to $13.7M in Q4 2020. For the entire year, the net loss decreased to $43M from $49.6M, attributed mainly to reduced R&D costs and improved financial discipline.

Savara Inc. (NASDAQ: SVRA), a biopharmaceutical company focused on rare respiratory diseases, announced the granting of an employee inducement award on March 14, 2022. The award includes options to purchase 40,000 shares of common stock at an exercise price of $1.05 per share, matching the closing price on the grant date. The options vest quarterly over a 10-year term, contingent on the employee's continued employment. Savara's lead program, molgramostim, is currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced its participation in Oppenheimer’s 32nd Annual Healthcare Conference on March 16, 2022, at 3:20 pm ET. The presentation will focus on their lead program, molgramostim, an inhaled treatment for autoimmune pulmonary alveolar proteinosis (aPAP), currently in Phase 3 development. A live webcast will be available on Savara’s website and archived for 90 days. Savara is dedicated to advancing therapies for rare respiratory diseases.